This inventor holds 2 USPTO granted patents. Top assignees: Daegu-Gyeongbuk Medical Innovation Foundation, Immunoforge Co., Ltd., S&k Therapeutics. Active years: 2026.
Company Filing History:
1 out of 10 
1 out of 1 
1 out of 1 Years Active: 2026
Title: Innovations by Hyo-Ji Kim in Autoimmune Disease Treatment
Introduction
Hyo-Ji Kim is a notable inventor based in Daegu, South Korea. He has made significant contributions to the field of medicine, particularly in the development of therapeutic agents for autoimmune diseases. His innovative work focuses on small-molecule compounds that target endosomal toll-like receptors.
Latest Patents
Hyo-Ji Kim holds a patent for "Small-molecule compounds for controlling endosomal toll-like receptors and therapeutic agent for autoimmune diseases using same." This patent describes antagonistic small-molecule compounds that inhibit TLR3/7/8/9 signaling pathways. The compounds have shown promising results in a systemic lupus erythematosus animal model. They not only prevent TNF-α secretion induced by various TLR agonists but also inhibit the production of inflammatory cytokines. This suggests their potential utility in preventing or treating autoimmune diseases, inflammatory diseases, and viral diseases.
Career Highlights
Hyo-Ji Kim is associated with S&K Therapeutics, where he continues to advance his research and development efforts. His work has garnered attention for its innovative approach to tackling complex health issues related to autoimmune conditions.
Collaborations
Hyo-Ji Kim collaborates with notable colleagues, including Doohyun Lee and Sangdun Choi. Their combined expertise enhances the research and development efforts at S&K Therapeutics.
Conclusion
Hyo-Ji Kim's innovative contributions to the field of autoimmune disease treatment highlight the importance of targeted therapies in modern medicine. His work continues to pave the way for advancements in therapeutic options for patients suffering from these challenging conditions.